{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:42:13Z","timestamp":1790638933046,"version":"4.1.0"},"reference-count":117,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y000773\/1"],"award-info":[{"award-number":["MR\/Y000773\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gates Foundation","award":["INV-031830"],"award-info":[{"award-number":["INV-031830"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Neglected tropical diseases (NTDs), particularly those with prominent cutaneous manifestations such as leishmaniasis, leprosy, and Buruli ulcer, represent a substantial global health burden, affecting hundreds of millions of people and perpetuating cycles of poverty and disability. Despite the current availability of treatment strategies, vaccines remain the most sustainable and cost-effective intervention that can reduce reliance on chemotherapeutics. However, vaccine research and development (R&amp;D) for these diseases face considerable challenges that cannot be overcome without a strategic shift in response by national and international health programmes and organisations, research funders, and the pharmaceutical industry. This paper draws on collective insights from the VALIDATE Network workshop on \u201cVaccines for Skin Neglected Tropical Diseases\u2014Progress and Challenges\u201d (Bogot\u00e1, Colombia, 5\u20138 May 2025). We advocate for a multisectoral shift across three critical pillars: i) an increase in funding for NTD vaccine R&amp;D, ii) integration of NTD vaccine R&amp;D into the preparedness and response policies by international agencies and local governments, and iii) fostering patient and public engagement and advocacy for NTD vaccine R&amp;D and implementation. Coordinated efforts across these three pillars will unlock the transformative potential of vaccines and substantially reduce the health, societal, and economic burdens from these diseases.<\/jats:p>","DOI":"10.1371\/journal.pntd.0014375","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:25:11Z","timestamp":1780680311000},"page":"e0014375","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accelerating vaccine research and development for skin neglected tropical diseases: A case for leishmaniasis, leprosy, and Buruli ulcer"],"prefix":"10.1371","volume":"20","author":[{"given":"Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Oliveira","family":"Novais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Adelaida","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Muhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila I.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao-Thy","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Vermaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VALIDATE Network Skin NTDs Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-8355","authenticated-orcid":true,"given":"Rajko","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"pntd.0014375.ref001","author":"WHO","year":"2021"},{"key":"pntd.0014375.ref002","author":"WHO","year":"2021"},{"key":"pntd.0014375.ref003","author":"WHO"},{"key":"pntd.0014375.ref004","volume-title":"Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases","author":"WHO","year":"2022","edition":"1"},{"issue":"5","key":"pntd.0014375.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012086","article-title":"Financial hardship among patients suffering from neglected tropical diseases: a systematic review and meta-analysis of global literature","volume":"18","author":"C Patikorn","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref006","doi-asserted-by":"crossref","first-page":"117094","DOI":"10.1016\/j.socscimed.2024.117094","article-title":"The role of economic factors in shaping and constituting the household burden of neglected tropical diseases of the skin: qualitative findings from Ghana and Ethiopia","volume":"356","author":"Y Hailemichael","year":"2024","journal-title":"Soc Sci Med"},{"issue":"2","key":"pntd.0014375.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009131","article-title":"The impact of Neglected Tropical Diseases (NTDs) on health and wellbeing in sub-Saharan Africa (SSA): a case study of Kenya","volume":"15","author":"EA Ochola","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0014375.ref008","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ijd.16636","article-title":"Climate change and the displaced person: how vectors and climate are changing the landscape of infectious diseases among displaced and migrant populations","volume":"62","author":"SH Choi","year":"2023","journal-title":"Int J Dermatol"},{"issue":"2","key":"pntd.0014375.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009760","article-title":"Individual risk perception and empirical social structures shape the dynamics of infectious disease outbreaks","volume":"18","author":"V d\u2019Andrea","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"pntd.0014375.ref010","author":"P Jacob","year":"2022"},{"key":"pntd.0014375.ref011","author":"WHO","year":"2023"},{"key":"pntd.0014375.ref012","author":"WHO","year":"2023"},{"issue":"2","key":"pntd.0014375.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011138","article-title":"Prevalence of post kala-azar dermal leishmaniasis (PKDL) and treatment seeking behavior of PKDL patients in Nepal","volume":"17","author":"AB Joshi","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref014","doi-asserted-by":"crossref","first-page":"107213","DOI":"10.1016\/j.ijid.2024.107213","article-title":"Post kala-azar dermal leishmaniasis burden at the village level in selected high visceral leishmaniasis endemic upazilas in Bangladesh","volume":"147","author":"D Ghosh","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pntd.0014375.ref015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4269\/ajtmh.18-0643","article-title":"Eligibility for local therapies in adolescents and adults with cutaneous Leishmaniasis from southwestern Colombia: a cross-sectional study","volume":"100","author":"AF Uribe-Restrepo","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0014375.ref016","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vaccine.2012.11.032","article-title":"The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas","volume":"31","author":"KM Bacon","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"pntd.0014375.ref017","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13090812","article-title":"Advances in leishmania vaccines: current development and future prospects","volume":"13","author":"A Ayala","year":"2024","journal-title":"Pathogens"},{"issue":"3","key":"pntd.0014375.ref018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/infdis\/168.3.699","article-title":"Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations","volume":"168","author":"KA Weigle","year":"1993","journal-title":"J Infect Dis"},{"issue":"2","key":"pntd.0014375.ref019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/S0950268800057964","article-title":"Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity","volume":"114","author":"CR Davies","year":"1995","journal-title":"Epidemiol Infect"},{"key":"pntd.0014375.ref020","doi-asserted-by":"crossref","first-page":"639801","DOI":"10.3389\/fcimb.2021.639801","article-title":"Revival of leishmanization and leishmanin","volume":"11","author":"T Pacheco-Fernandez","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"pntd.0014375.ref021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"CS Peacock","year":"2007","journal-title":"Nat Genet"},{"issue":"6","key":"pntd.0014375.ref022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/dnares\/dst031","article-title":"The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models","volume":"20","author":"F Real","year":"2013","journal-title":"DNA Res"},{"issue":"8","key":"pntd.0014375.ref023","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.4049\/jimmunol.1500752","article-title":"Cutaneous infection with Leishmania major mediates heterologous protection against visceral infection with Leishmania infantum","volume":"195","author":"A Romano","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"pntd.0014375.ref024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41541-022-00574-x","article-title":"Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis","volume":"7","author":"S Karmakar","year":"2022","journal-title":"NPJ Vaccines"},{"key":"pntd.0014375.ref025","doi-asserted-by":"crossref","first-page":"148803","DOI":"10.1016\/j.gene.2024.148803","article-title":"Genetic diversity of Leishmania donovani causing visceral and cutaneous leishmaniasis in the Western Ghats, India","volume":"928","author":"PA Fathima","year":"2024","journal-title":"Gene"},{"issue":"6","key":"pntd.0014375.ref026","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pt.2025.04.002","article-title":"Leishmania genomic adaptation: more than just a 36-body problem","volume":"41","author":"GF Sp\u00e4th","year":"2025","journal-title":"Trends Parasitol"},{"key":"pntd.0014375.ref027","article-title":"Case study for a vaccine against leishmaniasis","author":"J Alvar","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"pntd.0014375.ref028","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14760584.2021.1969231","article-title":"From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection","volume":"20","author":"G Volpedo","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"pntd.0014375.ref029","article-title":"Vaccine value profile for leishmaniasis","author":"PM Kaye","year":"2023","journal-title":"Vaccine"},{"issue":"19","key":"pntd.0014375.ref030","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"J Chakravarty","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0014375.ref031","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0031182017002116","article-title":"Chemotherapeutics of visceral leishmaniasis: present and future developments","volume":"145","author":"S Sundar","year":"2018","journal-title":"Parasitology"},{"issue":"4","key":"pntd.0014375.ref032","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"RN Coler","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"pntd.0014375.ref033","article-title":"Nucleoside hydrolase (NH36) domains induce T-cell cytokine responses in human visceral leishmaniasis","volume":"8","author":"MLB Santos","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"pntd.0014375.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH","volume":"11","author":"M Osman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014375.ref035","doi-asserted-by":"crossref","first-page":"101310","DOI":"10.1016\/j.omtm.2024.101310","article-title":"A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis","volume":"32","author":"BM Younis","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"pntd.0014375.ref036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-025-01070-8","article-title":"LmCen-\/- based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia","volume":"10","author":"T Boussoffara","year":"2025","journal-title":"NPJ Vaccines"},{"key":"pntd.0014375.ref037","doi-asserted-by":"crossref","first-page":"1598755","DOI":"10.3389\/fimmu.2025.1598755","article-title":"The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection","volume":"16","author":"DC Gomes","year":"2025","journal-title":"Front Immunol"},{"key":"pntd.0014375.ref038","article-title":"The F1F3 recombinant chimera of leishmania donovani-nucleoside hydrolase (NH36) and Its epitopes induce cross-protection against Leishmania (V.) braziliensis Infection in Mice","volume":"10","author":"MV Alves-Silva","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"pntd.0014375.ref039","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830200927","article-title":"Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD4+ cells are different from TH2 cells","volume":"20","author":"H Moll","year":"1990","journal-title":"Eur J Immunol"},{"issue":"6","key":"pntd.0014375.ref040","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.177.6.1797","article-title":"Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response","volume":"177","author":"JP Sypek","year":"1993","journal-title":"J Exp Med"},{"issue":"4","key":"pntd.0014375.ref041","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/IAI.71.4.2244-2246.2003","article-title":"Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses","volume":"71","author":"E Bourreau","year":"2003","journal-title":"Infect Immun"},{"issue":"6","key":"pntd.0014375.ref042","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.humimm.2009.01.007","article-title":"Th1\/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production","volume":"70","author":"LR Castellano","year":"2009","journal-title":"Hum Immunol"},{"issue":"12","key":"pntd.0014375.ref043","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1128\/IAI.70.12.6734-6740.2002","article-title":"Up-regulation of Th1-type responses in mucosal leishmaniasis patients","volume":"70","author":"O Bacellar","year":"2002","journal-title":"Infect Immun"},{"key":"pntd.0014375.ref044","doi-asserted-by":"crossref","first-page":"685296","DOI":"10.3389\/fcimb.2021.685296","article-title":"Mechanisms of immunopathogenesis in cutaneous leishmaniasis and post kala-azar dermal leishmaniasis (PKDL)","volume":"11","author":"G Volpedo","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"pntd.0014375.ref045","doi-asserted-by":"crossref","first-page":"1765843","DOI":"10.3389\/fimmu.2026.1765843","article-title":"Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape","volume":"17","author":"N de Vrij","year":"2026","journal-title":"Front Immunol"},{"issue":"3","key":"pntd.0014375.ref046","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pt.2026.01.005","article-title":"Breaking the deadlock in antigen discovery for Leishmania vaccines","volume":"42","author":"W Adriaensen","year":"2026","journal-title":"Trends Parasitol"},{"issue":"11","key":"pntd.0014375.ref047","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1038\/s41591-024-03146-9","article-title":"Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis","volume":"30","author":"V Parkash","year":"2024","journal-title":"Nat Med"},{"key":"pntd.0014375.ref048","author":"WHO","year":"2024"},{"key":"pntd.0014375.ref049","author":"WHO","year":"2025"},{"key":"pntd.0014375.ref050","first-page":"365","article-title":"Global leprosy (Hansen disease) update, 2024: beyond zero cases \u2013 what elimination of leprosy really means.","volume-title":"Weekly epidemiological record","author":"WHO","year":"2025"},{"issue":"6","key":"pntd.0014375.ref051","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(05)70117-1","article-title":"Leprosy elimination not yet in sight","volume":"5","author":"The Lancet Infectious Diseases.","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"pntd.0014375.ref052","article-title":"Hazards of setting targets to eliminate disease: lessons from the leprosy elimination campaign","volume":"348","author":"DNJ Lockwood","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"pntd.0014375.ref053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003658","article-title":"The missing millions: a threat to the elimination of leprosy","volume":"9","author":"WC Smith","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0014375.ref054","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.cmi.2018.02.022","article-title":"Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15","volume":"24","author":"E Cambau","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"24","key":"pntd.0014375.ref055","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","article-title":"BCG vaccine: WHO position paper, February 2018-recommendations","volume":"36","author":"WHO","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"pntd.0014375.ref056","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","article-title":"The role of BCG in prevention of leprosy: a meta-analysis","volume":"6","author":"MS Setia","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pntd.0014375.ref057","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0378-6323.31891","article-title":"Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis","volume":"73","author":"SP Zodpey","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"pntd.0014375.ref058","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/erv.09.161","article-title":"BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control","volume":"9","author":"CSC Merle","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"pntd.0014375.ref059","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00309-0","article-title":"BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial","volume":"9","author":"JR Glynn","year":"2021","journal-title":"Lancet Glob Health"},{"key":"pntd.0014375.ref060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fimmu.2018.00308","article-title":"Vaccines for leprosy and tuberculosis: opportunities for shared research, development, and application","volume":"9","author":"M Coppola","year":"2018","journal-title":"Front Immunol"},{"key":"pntd.0014375.ref061","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-031-24355-4_4","article-title":"Leprosy vaccines: developments for prevention and treatment.","volume-title":"Vaccines for neglected pathogens: strategies, achievements and challenges: focus on leprosy, leishmaniasis, melioidosis and tuberculosis","author":"H Wang","year":"2023"},{"issue":"2","key":"pntd.0014375.ref062","doi-asserted-by":"crossref","first-page":"127","DOI":"10.47276\/lr.76.2.127","article-title":"Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years","volume":"76","author":"P Sharma","year":"2005","journal-title":"Lepr Rev"},{"issue":"5","key":"pntd.0014375.ref063","doi-asserted-by":"crossref","first-page":"606","DOI":"10.25259\/IJDVL_1172_2023","article-title":"MIP vaccine in leprosy: a scoping review and future horizons","volume":"90","author":"T Narang","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"pntd.0014375.ref064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2473-2176\/3\/1\/00123","article-title":"Launching of immunization with the vaccine Mycobacterium indicus pranii for eradication of leprosy in India","volume":"3","author":"T G.P","year":"2017","journal-title":"IJVR"},{"key":"pntd.0014375.ref065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-018-0050-z","article-title":"LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection","volume":"3","author":"MS Duthie","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"7","key":"pntd.0014375.ref066","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.vaccine.2019.12.050","article-title":"A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1+ GLA\u2013SE) in healthy adults","volume":"38","author":"MS Duthie","year":"2020","journal-title":"Vaccine"},{"key":"pntd.0014375.ref067","author":"World Health Organization","year":"2021"},{"key":"pntd.0014375.ref068","author":"WHO","year":"2023"},{"key":"pntd.0014375.ref069","first-page":"752749","article-title":"Buruli-ulcer induced disability in Ghana: a study at apromase in the ashanti region","volume":"2012","author":"P Agbenorku","year":"2012","journal-title":"Plast Surg Int"},{"issue":"9","key":"pntd.0014375.ref070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.31128\/AJGP-08-23-6914","article-title":"An overview of Buruli ulcer in Australia","volume":"53","author":"CCW Wong","year":"2024","journal-title":"Aust J Gen Pract"},{"issue":"2","key":"pntd.0014375.ref071","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41564-023-01553-1","article-title":"Mosquitoes provide a transmission route between possums and humans for Buruli ulcer in southeastern Australia","volume":"9","author":"PT Mee","year":"2024","journal-title":"Nat Microbiol"},{"key":"pntd.0014375.ref072","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.onehlt.2021.100311","article-title":"Linking the Mycobacterium ulcerans environment to Buruli ulcer disease: progress and challenges","volume":"13","author":"L Dhungel","year":"2021","journal-title":"One Health"},{"issue":"11","key":"pntd.0014375.ref073","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001392","article-title":"Adequate wound care and use of bed nets as protective factors against Buruli Ulcer: results from a case control study in Cameroon","volume":"5","author":"J Landier","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014375.ref074","first-page":"100","article-title":"Delays in patient presentation and diagnosis for Buruli Ulcer (Mycobacterium ulcerans Infection) in Victoria, Australia, 2011-2017","volume":"4","author":"SP Coutts","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"7","key":"pntd.0014375.ref075","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/jcm.35.7.1696-1700.1997","article-title":"Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection","volume":"35","author":"BC Ross","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"11","key":"pntd.0014375.ref076","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5694\/mja2.52591","article-title":"Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement","volume":"222","author":"S Muhi","year":"2025","journal-title":"Med J Aust"},{"issue":"10232","key":"pntd.0014375.ref077","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"RO Phillips","year":"2020","journal-title":"Lancet"},{"key":"pntd.0014375.ref078","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/1471-2334-13-416","article-title":"Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections","volume":"13","author":"DP O\u2019Brien","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"8","key":"pntd.0014375.ref079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007689","article-title":"Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: relationship to bacterial load","volume":"13","author":"M Frimpong","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014375.ref080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006357","article-title":"Wound healing: natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease","volume":"12","author":"DP O\u2019Brien","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0014375.ref081","article-title":"The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER","volume":"10","author":"BS Hall","year":"2014","journal-title":"PLoS Pathog"},{"issue":"13","key":"pntd.0014375.ref082","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1084\/jem.20160662","article-title":"Mycolactone subverts immunity by selectively blocking the Sec61 translocon","volume":"213","author":"L Baron","year":"2016","journal-title":"J Exp Med"},{"key":"pntd.0014375.ref083","article-title":"The Mycobacterium ulcerans toxin mycolactone causes destructive Sec61-dependent loss of the endothelial glycocalyx and vessel basement membrane to drive skin necrosis","volume":"12","author":"LT-H Hsieh","year":"2025","journal-title":"Elife"},{"issue":"2","key":"pntd.0014375.ref084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004450","article-title":"Interferon-\u03b3 is a crucial activator of early host immune defense against Mycobacterium ulcerans infection in mice","volume":"10","author":"R Bieri","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-031-24355-4_5","article-title":"Current progress and prospects for a Buruli ulcer vaccine.","volume-title":"Vaccines for neglected pathogens: strategies, achievements and challenges: focus on leprosy, leishmaniasis, melioidosis and tuberculosis","author":"J Boakye-Appiah","year":"2023"},{"issue":"50","key":"pntd.0014375.ref086","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1016\/j.vaccine.2021.05.092","article-title":"Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis","volume":"39","author":"S Muhi","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"pntd.0014375.ref087","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/IAI.68.2.877-883.2000","article-title":"A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells","volume":"68","author":"KM George","year":"2000","journal-title":"Infect Immun"},{"issue":"6","key":"pntd.0014375.ref088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011394","article-title":"A human model of Buruli ulcer: the case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain","volume":"17","author":"S Muhi","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0014375.ref089","article-title":"Overexpression of a Mycobacterium ulcerans Ag85B-EsxH fusion protein in recombinant BCG improves experimental Buruli ulcer vaccine efficacy","volume":"10","author":"BE Hart","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014375.ref090","article-title":"A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection","volume":"19","author":"JK Boakye-Appiah","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref091","doi-asserted-by":"crossref","first-page":"488","DOI":"10.12688\/wellcomeopenres.22719.1","article-title":"A human model of Buruli ulcer: provisional protocol for a Mycobacterium ulcerans controlled human infection study","volume":"9","author":"S Muhi","year":"2024","journal-title":"Wellcome Open Res"},{"issue":"5","key":"pntd.0014375.ref092","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011979","article-title":"Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model","volume":"18","author":"S Muhi","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014375.ref093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012593","article-title":"Perceptions of a Buruli ulcer controlled human infection model: how, who, and why?","volume":"19","author":"S Muhi","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref094","author":"Center for Drug E","year":"2008"},{"issue":"1","key":"pntd.0014375.ref095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-013686","article-title":"European priority review vouchers for neglected disease product development","volume":"9","author":"DB Ridley","year":"2024","journal-title":"BMJ Glob Health"},{"key":"pntd.0014375.ref096","unstructured":"Sanofi. FDA grants priority review for Sanofi\u2019s dengue vaccine candidate, PRNewswire. Sanofi US News; 2018."},{"key":"pntd.0014375.ref097","unstructured":"Valneva. Valneva Announces U.S. FDA Approval of World\u2019s First Chikungunya Vaccine, IXCHIQ; 2023."},{"key":"pntd.0014375.ref098","unstructured":"Nordic B. Bavarian Nordic receives U.S. FDA approval of chikungunya vaccine for persons aged 12 and older. 2025."},{"issue":"12","key":"pntd.0014375.ref099","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-015933","article-title":"The priority review voucher: a misconceived quid pro quo","volume":"9","author":"P Olliaro","year":"2024","journal-title":"BMJ Glob Health"},{"key":"pntd.0014375.ref100","first-page":"1","article-title":"Development impact bonds in developing countries: an emerging innovation for achieving social outcomes","author":"AK Mishra","year":"2022","journal-title":"J Soc Econ Dev"},{"issue":"11","key":"pntd.0014375.ref101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005000","article-title":"Novel financing model for neglected tropical diseases: development impact bonds applied to sleeping sickness and rabies control","volume":"10","author":"SC Welburn","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref102","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fvets.2017.00032","article-title":"Rabies control: could innovative financing break the deadlock?","volume":"4","author":"SC Welburn","year":"2017","journal-title":"Front Vet Sci"},{"issue":"11","key":"pntd.0014375.ref103","article-title":"Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases","volume":"17","author":"Z Ma","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref104","first-page":"1","article-title":"Public-private partnerships and the landscape of neglected tropical disease research: the shifting logic and spaces of knowledge production","author":"H Ferpozzi","year":"2023","journal-title":"Minerva"},{"key":"pntd.0014375.ref105","author":"WHO","year":"2025"},{"issue":"11","key":"pntd.0014375.ref106","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1473-3099(23)00589-3","article-title":"The TB Vaccine Accelerator Council: harnessing the power of vaccines to end the tuberculosis epidemic","volume":"23","author":"TA Ghebreyesus","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pntd.0014375.ref107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004304","article-title":"Community-led strategies for communicable disease prevention and management in low- and middle- income countries: a mixed-methods systematic review of health, social, and economic impact","volume":"5","author":"PP Indravudh","year":"2025","journal-title":"PLOS Glob Public Health"},{"issue":"6","key":"pntd.0014375.ref108","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1111\/hex.13615","article-title":"Applying patient and public involvement in preclinical research: a co-created scoping review","volume":"25","author":"P Carroll","year":"2022","journal-title":"Health Expect"},{"issue":"2","key":"pntd.0014375.ref109","article-title":"Involving patients in drug development for Neglected Tropical Diseases (NTDs): a qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development","volume":"18","author":"MDM Castro","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014375.ref110","author":"WHO","year":"2019"},{"issue":"34","key":"pntd.0014375.ref111","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: definition, scope and determinants","volume":"33","author":"SAGE Working Group on Vaccine Hesitancy","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"pntd.0014375.ref112","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/vaccines11020409","article-title":"Healthcare access and experiences of racial discrimination as predictors of general vaccine hesitancy","volume":"11","author":"S CarlLee","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"pntd.0014375.ref113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11524-021-00588-1","article-title":"Confidence and hesitancy during the early roll-out of covid-19 vaccines among black, hispanic, and undocumented immigrant communities: a review","volume":"99","author":"SM McFadden","year":"2022","journal-title":"J Urban Health"},{"issue":"4","key":"pntd.0014375.ref114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2105\/AJPH.2020.306047","article-title":"Preparing for SARS-CoV-2 vaccines in US immigrant communities: strategies for allocation, distribution, and communication","volume":"111","author":"EH Clark","year":"2021","journal-title":"Am J Public Health"},{"issue":"8","key":"pntd.0014375.ref115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012391","article-title":"The psychosocial impacts of skin-neglected tropical diseases (SNTDs) as perceived by the affected persons: a systematic review","volume":"18","author":"DL Alderton","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0014375.ref116","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1080\/21645515.2019.1629254","article-title":"\u201cRunning the Gauntlet\u201d: formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a \u201cCall to Action\u201d","volume":"15","author":"ME Bottazzi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"pntd.0014375.ref117","year":"2025"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:25:25Z","timestamp":1780680325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014375"}},"subtitle":[],"editor":[{"given":"Nicholas J.","family":"Mantis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":117,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014375","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}